Subscribe
gguy / Shutterstock.com
6 November 2025NewsCareersTom Phillips

WBD adds litigation firepower in Silicon Valley with DLA Piper veteran

Womble Bond Dickinson has expanded its West Coast footprint with the addition of a seasoned patent litigator, strengthening the firm’s life sciences capabilities amid rising IP disputes and rapid biotech innovation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Careers
WBD hires patent partner for LA office
23 May 2024   The patent attorney’s expertise spans artificial intelligence, machine learning and medical devices.
Biotechnology
Womble Bond Dickinson boosts IP arm with patent expert
29 September 2022   New partner specialises in chemical-related tech | USPTO-registered litigator is also certified licensing professional | Appointment follows several hires in firm’s patents department.


Editor's picks

New AIPLA president calls for greater certainty in US patent law
Americas
New AIPLA president calls for greater certainty in US patent law
6 November 2025

Editor's picks

Americas
New AIPLA president calls for greater certainty in US patent law
6 November 2025
Americas
Squires: ‘Inherited patent backlog was an absolute dumpster fire’
1 November 2025
Americas
Why AI is changing the patent rules faster than anyone can keep up
24 October 2025
Americas
LSPN panel unpacks critical IP risks in deal-making
23 October 2025
Americas
A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order
23 October 2025
Americas
Data and delivery: Inside AI's inventorship dilemma
21 October 2025

More features

Pfizer can’t block Novo Nordisk’s $10bn takeover deal
New AIPLA president calls for greater certainty in US patent law
Regeneron and CureVac: UPC ‘cannot be ignored’
US generics company wins patent battle over Merck Serono’s blockbuster MS drug
Novartis counsel warns: ‘Don’t let AI develop without our input’
Squires: ‘Inherited patent backlog was an absolute dumpster fire’
Is Hatch-Waxman litigation for orphan drugs working?
Delegates descend upon Washington, DC for AIPLA Annual Meeting